LLY
Eli Lilly: explosive growth and 95% Buy ratings, but the stock has nearly caught its targets
Revenue up 45%, a three-of-four Financial Scorecard, and 94.52% of 20 analysts rating Buy — yet Eli Lilly trades just 3% below its all-time high at 41x earnings, and the average target of $1,229.19 implies only about 7% upside. Current price: $1,149.75.
drug-developmentbiotechnologychronic-disease